Use of a pharmaceutical composition in the manufacture of a medicament formulated for local or direct administration into a cerebral ventricle for treatment of delayed cerebral ischemia due to a brain injury in a human, the pharmaceutical composition comprising a flowable, sustained release microparticulate composition comprising a pharmaceutical carrier and a therapeutic amount of a therapeutic agent selected from: a dihydropyridine L-type voltage dependent calcium channel inhibitor, an endothelin (ET) receptor antagonist, a transient receptor potential (TRP) channel antagonist； wherein the pharmaceutical carrier comprises one or more of sodium carboxymethylcellulose, sorbitol, hyaluronic acid, or dextran； and each microparticle comprises a polymer matrix having a therapeutic agent dispersed throughout the microparticle, such that the therapeutic agent is not centrally located in a core surrounded by a coating.
